Clinical Trial Update: Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating the combination of erlotinib and AT-101 in advanced non-small cell lung cancer with EGFR activating mutations was terminated, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)
• Tarceva (erlotinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-11-20